Dermata Therapeutics Warrant
DRMAW
DRMAW was delisted on the 17th of August, 2026.
5 hedge funds and large institutions have $11K invested in Dermata Therapeutics Warrant in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.
3.34% more ownership
Funds ownership: 0% → 3.34% (+3.3%)
0% more funds holding
Funds holding: 5 → 5 (0)
83% less capital invested
Capital invested by funds: $64K → $11K (-$53K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$1.24K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$70 |
DRMAW Hedge Fund Activity: Q4 2022 in Review
5 institutional investors reported a position in Dermata Therapeutics Warrant (DRMAW) for Q4 2022, worth a combined $11K — down 83% from $64K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new DRMAW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Bank of America, opening a new position worth an estimated $3. The largest seller was Warberg Asset Management, cutting an estimated $1.24K.
- 5 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $11K of Dermata Therapeutics Warrant stock for Q4 2022, down 83% quarter-over-quarter.
- 1 fund opened new Dermata Therapeutics Warrant positions in Q4 2022 and 0 closed out, a net change of +1 holder.
- The largest Dermata Therapeutics Warrant buyer in Q4 2022 was Bank of America, an estimated $3 added.
- The largest Dermata Therapeutics Warrant seller in Q4 2022 was Warberg Asset Management, an estimated $1.24K sold.
Based on aggregated 13F filings for Q4 2022.